Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan

13 Oct 2015

The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.

Infirst HealthcareLtd. lags behind its expectations for introducing reformulated OTC drugs but is right where it wants to be with the UK launch of a cocoa extract-containing cough syrup and the planned launch of a lipid-formatted ibuprofen product.

The London firm on Oct. 8 said its Unicough cough/cold oral suspension (diphenhydramine 14mg, ammonium chloride 135mg and levomenthol 1.1mg...